Drugs / Allogeneic bone marrow-derived mesenchymal stromal cells
Allogeneic bone marrow-derived mesenchymal stromal cells
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT02150551 | Jun → Sep 2018 | inflammatory bowel disease | Catherine Bollard | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Allogeneic bone marrow-derived mesenchymal stromal cells | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02150551 ↗ |
| Modality | Cell therapy | “infuse donor bone marrow mesenchymal stromal cells intravenously” NCT02150551 ↗ |
| Route | Intravenous | “administered intravenously (IV)” NCT02150551 ↗ |